Xuanzhu Biopharmaceutical Co (FRA:V59) Total Long-Term Assets: €97.96 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V59 Xuanzhu Biopharmaceutical Co Ltd FRA:V59
11 GF Score
Price €1.31
! 1 Warning Sign
View Full Analysis

What is Xuanzhu Biopharmaceutical Co Total Long-Term Assets?

Xuanzhu Biopharmaceutical Co FRA:V59 +3.00% 11 Total Long-Term Assets is €97.96 Mil as of Dec. 2025. GuruFocus rates FRA:V59 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Xuanzhu Biopharmaceutical Co's Total Long-Term Assets for the quarter that ended in Dec. 2025 was €97.96 Mil.

Xuanzhu Biopharmaceutical Co Total Long-Term Assets Related Terms

Xuanzhu Biopharmaceutical Co Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Xuanzhu Biopharmaceutical Co's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xuanzhu Biopharmaceutical Co Total Long-Term Assets Chart

Xuanzhu Biopharmaceutical Co Annual Data
Trend Dec23 Dec24 Dec25
Total Long-Term Assets
99.99 108.56 97.96

Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets 99.99 0.00 108.56 100.23 97.96
FRA:V59
11GF Score
Xuanzhu Biopharmaceutical Co Ltd FRA:V59
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xuanzhu Biopharmaceutical Co Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €97.96 Mil mean?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a Total Long-Term Assets of €97.96 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Xuanzhu Biopharmaceutical Co and its competitors.
Is Xuanzhu Biopharmaceutical Co's Total Long-Term Assets too high?
Xuanzhu Biopharmaceutical Co's current Total Long-Term Assets is €97.96 Mil. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's Total Long-Term Assets compare to ZTS?
Xuanzhu Biopharmaceutical Co's Total Long-Term Assets of €97.96 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. Xuanzhu Biopharmaceutical Co's current Total Long-Term Assets is €97.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a current Total Long-Term Assets of €97.96 Mil. The current Total Long-Term Assets is €97.96 Mil. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (FRA:V59), the current Total Long-Term Assets is €97.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xuanzhu Biopharmaceutical Co Business Description

Other Exchanges 02575:Hong Kong
Address Zhubang 2000 Business Center, 2107, Building 2, Balizhuang Xili, Chaoyang District, Beijing, CHN
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score

Get the complete analysis for FRA:V59

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price